Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Products
Citizenship »
« Back
Careers
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor overview
Stock information
Press releases
Events
SEC filings
Corporate governance
Investor presentations
Investor FAQs
Email alerts

Investor contact

For investor related questions, please email

investors@aclaristx.com

Media contact
& resources »

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

July 7, 2020

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

June 17, 2020

Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19

June 3, 2020

Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress

Events

Jun 17, 2020
8:30 AM EDT

Aclaris Therapeutics Announces Investigator-Initiated Trial of ATI-450 for CRS in Hospitalized Patients with COVID-19

Jun 3, 2020
1:00 PM EDT

Aclaris Therapeutics, Inc. at Jefferies Virtual Healthcare Conference

Feb 25, 2020
5:00 PM EST

Q4 2019 Aclaris Therapeutics Inc. Earnings Conference Call

Feature presentation

More presentations coming soon.

Aclaris - Footer Menu

Terms of use
Privacy policy
Media resources
Contact us

© 2020 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.